

## Special Issue

# Developments, Challenges and Uncertainties in Delivering Stereotactic Ablative Body Radiotherapy to Solid Tumours

### Message from the Guest Editors

SABR (Stereotactic Ablative Body Radiotherapy) is a form of highly conformal image guided radiotherapy. It is now an established and routine treatment for early-stage lung cancer. It has an evolving role in metastatic cancer. The aim of this Special Issue is to highlight new research addressing uncertainties and new developments in SABR. This may include research on new technological innovations, new treatment strategies, and rare indications for treatment. Examples of this may include the use of new image guidance such as on an MRI linear accelerator, new indications for treatment, and single-fraction SABR. We invite researchers and clinicians to submit original research articles, review papers, case studies, and clinical trial reports that explore these themes. Your contributions will be instrumental in advancing our understanding of SABR.

---

### Guest Editors

Dr. Crispin T. Hiley

1. Research Department of Oncology, University College London, London, UK
2. The Francis Crick Institute, London, UK

Dr. Iain Phillips

Edinburgh Cancer Centre, NHS Lothian, Edinburgh EH4 2XU, UK

---

### Deadline for manuscript submissions

closed (30 April 2026)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/235630](https://mdpi.com/si/235630)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)